Vaccine

Draganfly Completes Over 300 EMS Drone Delivery Test Flights in Texas

Retrieved on: 
Thursday, October 28, 2021
Engineering, Technology, FSE, Aircraft pilot, Vaccine, EMS, Organization, CSE, USAF, NASDAQ, Agriculture, FAA, Life, Learning, Software, LLC, Company, CEO, Federal Aviation Administration, Solution, Artificial intelligence, United States Air Force, GLOBE, AI, Beekeeping, Risk management, Airline

Los Angeles, CA., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce that it has successfully completed over 300 daytime drone delivery test flights with EMS personnel in Texas.

Key Points: 
  • Los Angeles, CA., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (Draganfly or the Company), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce that it has successfully completed over 300 daytime drone delivery test flights with EMS personnel in Texas.
  • The intake includes professional drone operators and former US Air Force (USAF) personnel who have operational and piloting experience on multiple drone systems including the MQ-9 Reaper RPA.
  • Pilots and personnel are being taken through various scenarios while learning the drone techniques required to meet rigorous standards.
  • According to Beroe Inc. , the EMS market for drone services is estimated to grow by 25% between 2019 and 2025.

Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of ‘1104 in Eosinophilic Esophagitis

Retrieved on: 
Thursday, October 28, 2021
Safety, MTB, Esophagus, PHASE 2, Patient, Medicine, Steroid, EOE, Eosinophilic esophagitis, Eosinophil, Immune system, Rheumatoid arthritis, Autoimmunity, GLOBE, Allergy, Pharmaceutical industry, Vaccine

The Phase 2, randomized, double-blind, placebo-controlled trial will evaluate the safety and efficacy of1104 in adults with EoE.

Key Points: 
  • The Phase 2, randomized, double-blind, placebo-controlled trial will evaluate the safety and efficacy of1104 in adults with EoE.
  • Revolo Bio is advancing 1104 through two Phase 2 trials: one in patients with eosinophilic esophagitis (EoE) and one in patients with allergen sensitivity, while exploring its potential for other allergic diseases.
  • 1104 is a peptide derived from a natural immune-regulatory protein and is entering phase 2 clinical trials for patients with eosinophilic esophagitis (EoE) and allergic disease.
  • The disease-agnostic mechanism of action of Revolo Biotherapeutics assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time

Retrieved on: 
Thursday, October 28, 2021
Technology, Lighthouse, NGS, Infection, Investor, Precision medicine, Webcast, Nadine Opgen-Rhein, Solution, Finance, Broadcasting, Vaccine, Pharmaceutical industry

Following the conclusion of the conference call, a replay will be available through November 25, 2021.

Key Points: 
  • Following the conclusion of the conference call, a replay will be available through November 25, 2021.
  • The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Companys website at www.opgen.com .
  • A replay of the webcast will be available following the conclusion of the call and will be archived on the Companys website under Financials & Filings.
  • OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.

Vietnam leads the way with SOS Stool Method to diagnose TB

Retrieved on: 
Thursday, October 28, 2021
Sputum, Tuberculosis, Research, Diagnosis, Pediatrics, Disease, Method, Stomach, KNCV, NTP, GeneXpert MTB/RIF, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Child, Union, Journal of Clinical Microbiology, Nose, SOS, Mark R. Dybul, Margaret Chan, Time, Conference, TB, Simple, WHO, Health in Vietnam, GLOBE, Parent, Journal, HIV, Mouth, Vaccine, Medical device, Furniture

Vietnam, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vietnam is the first country in the world to routinely use an innovative method to diagnose tuberculosis (TB) using stool.

Key Points: 
  • Vietnam, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vietnam is the first country in the world to routinely use an innovative method to diagnose tuberculosis (TB) using stool.
  • The Pediatric TB Operational Sustainability Expertise Exchange (POSEE) Taskforce also describes the benefits of using stool to diagnose TB.As the SOS Stool Method is published in the peer reviewed Journal of Clinical Microbiology , many other countries are expected to follow Vietnams example and use this method.
  • Extended research such as head-to-head comparisons with other stool processing methods (FIND and TB Speed study) and the cost effectiveness of the SOS Stool Method (SOS-TBIM study) - have since be done.
  • Thao: The SOS Stool Method made my sons diagnosis and treatment much more accurate and easier.

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

Retrieved on: 
Thursday, October 28, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Safety, MAA, European Academy of Allergy and Clinical Immunology, Research, Vitiligo, Disease, BID, Knowledge, Annual report, Depigmentation, European Medicines Agency, Melanocyte, EMA, Security (finance), U.S. Securities and Exchange Commission, Patient, FDA, INT, Food, Face, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Life, Atopic dermatitis, Marketing, Company, Congress, Body surface area, VNS, COVID-19, Inflammation, Skin, AD, JAK, Program, Hidradenitis suppurativa, Solution, Classification, Therapy, BSA, Population, Prevalence, Week, Vaccine, Pharmaceutical industry, Cosmetics, TRuE-V, Ruxolitinib Cream, Incyte Dermatology, Incyte, TRUE-V, RUXOLITINIB CREAM, INCYTE DERMATOLOGY, INCYTE

Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement.
  • In the TRuE-V studies, patients using ruxolitinib cream did not report clinically significant application site reactions, and the overall safety profile was consistent with previous study data.
  • Ruxolitinib cream is an investigational novel cream formulation of Incytes selective JAK1/JAK2 inhibitor ruxolitinib.
  • Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.

$225+ Billion Healthcare Logistics Market - Global Outlook & Forecast 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 28, 2021
Health, Other Health, AmerisourceBergen, Medication, USD, Vaccine, Industry, DB Schenker, CEVA Logistics, Conditional sentence, FedEx, United Parcel Service, COVID-19, Growth, CAGR, IOT, Deutsche Post, COVID, Population, Prevalence, Kuehne + Nagel, AI, Pet, Pharmaceutical industry

The "Healthcare Logistics Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Healthcare Logistics Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global healthcare logistics market size was valued at USD 144.28 billion in 2020 and is expected to reach USD 226.57 billion by 2026, growing at a CAGR of 7.8%.
  • Covid 19 vaccine propelled the demand for healthcare logistics in the forecast period.
  • The study considers a detailed scenario of the present healthcare logistics market and its market dynamics for the period 2021-2026.

$5.66 Billion Vaccine Storage and Packaging Market - Global Outlook & Forecast 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 28, 2021
Packaging, Pharmaceutical, Health, Manufacturing, Research, Technology, Vaccine, Disease, Industry, Knowledge, APAC, RFID, Vaccination, Patient, FedEx, Immunization, BFS, Anthrax Vaccine Immunization Program, Government, COVID-19, Nature, Growth, Awareness, WHO, Temperature, Population, Prevalence, Coronavirus

The "Vaccine Storage and Packaging Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vaccine Storage and Packaging Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 outbreak has led to intensifying demand for vaccines to fight the disease; thus, it has contributed to the growth of the global vaccine storage & packaging market.
  • The prevalence of COVID-19 has provided vast opportunities to the vaccine freezers, refrigerators, ampoules, vials, and other packaging material providers.
  • COVID-19 has enabled the key vaccine players to partner with the key vendors in the vaccine storage equipment market.

Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies

Retrieved on: 
Thursday, October 28, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Genetics, Takeda, Disease, NIH, CAR, Stanford University, Cell, NIAID, Crystal Mackall, Degenerative disease, National, Pediatrics, Inflammation, Lists of diseases, National Institute, Haematopoietic system, Gene, Immune system, Division, Health, HIV, National Institute of Allergy and Infectious Diseases, Engineering, Biology, Research, Blood, Virology, UCSF School of Medicine, Immunodeficiency, Ernest, HSC, University of California, Genetics, Stanford University School of Medicine, Hemoglobinopathy, Infection, Hospital, UCSF, Microbiology, Society, Transplant, University, Cancer, Patient, Stem cell, Fred Hutchinson Cancer Research Center, SAB, Physician-scientist, Pharmaceutical industry, Vaccine, Medical device

We are excited to have assembled such an accomplished and diverse group of academic, scientific and clinical experts to serve on our scientific advisory board, said Robert Peters, Ph.D., chief scientific officer of Ensoma.

Key Points: 
  • We are excited to have assembled such an accomplished and diverse group of academic, scientific and clinical experts to serve on our scientific advisory board, said Robert Peters, Ph.D., chief scientific officer of Ensoma.
  • Her work includes utilizing transposons and designer nucleases within adenoviral vectors for achieving permanent treatment effects.
  • Our Engenious gene therapy platform is the first to precisely engineer any or all hematopoietic and immune cells with a one-time, off-the-shelf in vivo treatment.
  • Ensoma is supported by top-tier investors, a strategic collaboration with Takeda and a passionate team committed to a bold, global vision for gene therapy.

An Inhaled Therapeutic Developed At Texas A&M Has Been Shown To Be Effective Against Most Known Respiratory Infections, Including COVID-19

Retrieved on: 
Thursday, October 28, 2021
Research, Pharmaceutical, Oncology, Infectious Diseases, Hospitals, University, Education, Clinical Trials, Science, Biotechnology, FDA, Health, MD Anderson Cancer Center, MD, University, Cough, Twitter, Virus, Texas Tech University Health Sciences Center, Office of Inspector General, U.S. Department of Health and Human Services, Food, Pandemic, Bryan–College Station, Technology, Medicine, Distinguishing, List of life sciences, Clinical trial, Dentistry, CEO, COVID-19, Nursing, Bacteria, U.S. Department of Defense Strategy for Operating in Cyberspace, Public health, Texas A&M Health Science Center, Food and Drug Administration, Doctor of Philosophy, Pharmacy, Patient, CJ ENM, Pharmaceutical industry, Vaccine

Researchers at Texas A&M University Health Science Center ( Texas A&M Health ) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.

Key Points: 
  • Researchers at Texas A&M University Health Science Center ( Texas A&M Health ) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.
  • Patients in the trial treated with inhaled PUL-042 showed improvement in cough and shortness of breath more quickly than those who received a placebo dummy treatment.
  • Inhaled PUL-042 stimulates the lungs innate immune system, protecting against a wide variety of respiratory pathogens.
  • It also has potential utility for other patient populations which we plan to explore, including immunosuppressed cancer patient.

Embleema and George Washington University-led Consortium Wins FDA Contract to Advance the Fight Against Infectious Disease Outbreaks

Retrieved on: 
Thursday, October 28, 2021
University, Data Management, Education, Technology, FDA, Health, General Health, Research, Infectious Diseases, Software, Science, George Washington University, Research, Molecular medicine, Ecosystem, Database, Vaccine, DRS, Genomics, Crandall, FDA, Temple University, Food, Pandemic, Severe acute respiratory syndrome coronavirus 2, Simonyan, CEO, ARGOS, GW, Microbiology, Biochemistry, Therapy, Weatherall Institute of Molecular Medicine, Pharmaceutical industry, Medical device

Embleema, a New Jersey-based healthcare technology company, has partnered with investigators at The George Washington University (GW) and Temple University (TU) to advance the Food and Drug Administrations (FDA) Database for Reference Grade Microbial Sequences (FDA-ARGOS).

Key Points: 
  • Embleema, a New Jersey-based healthcare technology company, has partnered with investigators at The George Washington University (GW) and Temple University (TU) to advance the Food and Drug Administrations (FDA) Database for Reference Grade Microbial Sequences (FDA-ARGOS).
  • Embleema was awarded a contract worth $1,992,223 by the FDA for the development of quality matrix tools for FDA-ARGOS containing regulatory grade reference genomes for diagnostic use and regulatory science.
  • It is also clear that regulators need a sustainable, evolving ARGOS ecosystem that can be continuously enriched with novel information on existing and emerging pathogens.
  • Embleemas standard technology platform accelerates personalized medicine by expediting evidence generation and regulatory reviews of new treatments.